Related Experiment Video

Updated: Apr 27, 2026

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

2.0K

Primary treatment of kawasaki disease with corticosteroids

Swati Singhal1, Devendra Mishra2, Sumod Kurien3

  • 1Senior Resident, Department of Paediatrics, Maulana Azad Medical College and Lok Nayak Hospital , New Delhi, India .

Journal of Clinical and Diagnostic Research : JCDR
|July 5, 2014
PubMed

Insights

Kawasaki disease (KD) is a leading cause of acquired heart disease in children. This case study explores initial treatment with aspirin and corticosteroids for KD, discussing its implications.

Area of Science:

  • Pediatric Cardiology
  • Immunology
  • Rheumatology

Background:

  • Kawasaki disease (KD) is the primary cause of acquired pediatric heart disease globally.
  • Standard initial therapy for KD involves aspirin and intravenous immunoglobulin (IVIG) to prevent coronary artery aneurysms.
  • The role of corticosteroids in initial KD treatment remains a subject of clinical debate.

Observation:

  • This report details the case of a one-year-old child diagnosed with Kawasaki disease.
  • The child received initial treatment comprising aspirin and corticosteroids.
  • The clinical course and outcomes following this therapeutic approach were observed.

Findings:

  • The case illustrates the use of aspirin and corticosteroids as an initial management strategy for Kawasaki disease.
  • Pertinent clinical issues related to this treatment protocol are discussed.
  • This highlights a specific therapeutic option for KD management.

Implications:

  • This case contributes to the ongoing discussion regarding the optimal initial treatment for Kawasaki disease.
  • Understanding the outcomes of corticosteroid use in KD is crucial for refining pediatric cardiac care guidelines.
  • Further research may clarify the precise role of corticosteroids in preventing cardiac complications in KD.

Keywords:
Coronary aneurysmsCorticosteroidKawasaki diseaseManagementOutcome

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.4K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
689
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
539
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
342
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
583